MEDO.ai is a health-tech startup company that envisions transforming ultrasound into the stethoscope of the 21st century. MEDO builds cutting edge artificial intelligence that pairs with ultrasound devices to facilitate novice users' ability to detect common and critical conditions.
MEDO’s cloud-based ultrasound platform, which is cleared by the US Food and Drug Administration, is capable of segmenting anatomical structures from ultrasound images and cine clips, visualizing them in 3D and translating them into relevant clinical information in a couple of seconds.

The Medo platform is vendor-neutral and enables quick, objective and reproducible workflows, not possible with conventional methods. The platform significantly lowers the expertise required to diagnose common and critical conditions using ultrasound, making it accessible to all. Medo currently simplifies several use cases, two of which are:
- Enabling novice users to screen for developmental hip dysplasia - a condition wh...
MEDO.ai is a health-tech startup company that envisions transforming ultrasound into the stethoscope of the 21st century. MEDO builds cutting edge artificial intelligence that pairs with ultrasound devices to facilitate novice users' ability to detect common and critical conditions.
MEDO’s cloud-based ultrasound platform, which is cleared by the US Food and Drug Administration, is capable of segmenting anatomical structures from ultrasound images and cine clips, visualizing them in 3D and translating them into relevant clinical information in a couple of seconds.

The Medo platform is vendor-neutral and enables quick, objective and reproducible workflows, not possible with conventional methods. The platform significantly lowers the expertise required to diagnose common and critical conditions using ultrasound, making it accessible to all. Medo currently simplifies several use cases, two of which are:
- Enabling novice users to screen for developmental hip dysplasia - a condition which results in arthritis if not treated.
- Automatically classifying thyroid nodules as benign vs. potentially malignant, a process which is normally time consuming, repetitive, and very subjective.
More information

Employees

David Quail
Admin
David Quail Product Product focused entrepreneur. Focused on AI for the last decade.
Siyavash G. Nia
Admin
Siyavash G. Nia member of MEDO.ai